Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial - Archive ouverte HAL Access content directly
Journal Articles European Heart Journal Year : 2015

Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial

(1, 2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (9) , (9) , (10) , (10) , (9) , (11) , (12) , (6) , (13) , (14) , (9) , (9)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Craig Stolen
  • Function : Author
Scott Meyer
  • Function : Author
Kenneth Stein
  • Function : Author
Agnes Ramuzat
  • Function : Author
Bernd Schubert
  • Function : Author
Doug Daum
  • Function : Author
Petr Neuzil
  • Function : Author
Nicholas Wold
  • Function : Author
Stephen Ruble
  • Function : Author

Abstract

AIM: The neural cardiac therapy for heart failure (NECTAR-HF) was a randomized sham-controlled trial designed to evaluate whether a single dose of vagal nerve stimulation (VNS) would attenuate cardiac remodelling, improve cardiac function and increase exercise capacity in symptomatic heart failure patients with severe left ventricular (LV) systolic dysfunction despite guideline recommended medical therapy. METHODS: Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LV end systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers. RESULTS: Of the 96 implanted patients, 87 had paired datasets for the primary endpoint. Change in LVESD from baseline to 6 months was -0.04 ± 0.25 cm in the therapy group compared with -0.08 ± 0.32 cm in the control group (P = 0.60). Additional echocardiographic parameters of LV end diastolic dimension, LV end systolic volume, left ventricular end diastolic volume, LV ejection fraction, peak V02, and N-terminal pro-hormone brain natriuretic peptide failed to show superiority compared to the control group. However, there were statistically significant improvements in quality of life for the Minnesota Living with Heart Failure Questionnaire (P = 0.049), New York Heart Association class (P = 0.032), and the SF-36 Physical Component (P = 0.016) in the therapy group. CONCLUSION: Vagal nerve stimulation as delivered in the NECTAR-HF trial failed to demonstrate a significant effect on primary and secondary endpoint measures of cardiac remodelling and functional capacity in symptomatic heart failure patients, but quality-of-life measures showed significant improvement.

Dates and versions

hal-01742982 , version 1 (26-03-2018)

Identifiers

Cite

Faiez Zannad, Gaetano de Ferrari, Anton Tuinenburg, David Wright, Josep Brugada, et al.. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. European Heart Journal, 2015, 36 (7), pp.425 - 433. ⟨10.1093/eurheartj/ehu345⟩. ⟨hal-01742982⟩
44 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More